UNSPSC 51292921: Imipramine hydrochloride

This classification denotes a tricyclic antidepressant with the molecular formula C19H24N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BKE5Q1J60U, chemically known as 5,6-dihydro-n-(3-(dimethylamino)propyl)-11h-dibenz(b,e)azepine but more generally known as imipramine hydrochloride, which bears US NIH Compound Identifier 3696. European Medicines Agency schedules Imipramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02644MIG.

Most nations, for tariff and trade purposes, schedule imipramine hydrochloride under HS 29339990. As of Q4 2014, IMIPRAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Imipramine hydrochloride bears US NLM identifiers UMLS ID C0589978 and NCI Concept Code C29116. SMILES: CN(C)CCCN1C2CCCCC2CCC3C1CCCC3.CL.

UNSPSC 51292921 Imipramine hydrochloride is a Commodity code that does not reflect the actual work state and local governments are buying under this classification. The three most recent opportunities tagged to this code solicit naloxone and drug deactivation systems, a direct-to-manufacturer prescription program inquiry, and generic multi-source pharmaceuticals and OTC products — none of which center on imipramine hydrochloride, a tricyclic antidepressant. The code appears to be a source data tagging error; imipramine is a legacy psychiatric medication with limited current procurement activity in state and local public health and corrections purchasing, whereas the solicitations shown track opioid-reversal and broad-spectrum pharmaceutical supply contracting.

The recent opportunities involve state health agencies, county health departments, and multistate cooperative purchasing alliances. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, inclusive of shipping costs. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 regarding direct-to-manufacturer prescription programs, designed as a preliminary information-gathering phase before formal solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with contract terms effective July 1, 2026 and participation from Oregon. Activity spans Florida, Texas, Minnesota, and multistate cooperative membership, but the mismatch between the commodity code and recent solicitations suggests limited direct applicability to imipramine procurement.